Where pharma's hidden powerhouse sits between Asia and Europe

India's pharmaceutical ingredients fuel Swiss re-export boom to global markets

Switzerland imported $232.5 million worth of pharmaceutical chemical ingredients from India in 2025, according to Swiss Federal Customs data, establishing the world's 4th largest economy as a critical upstream supplier to one of Europe's most sophisticated drug manufacturing hubs.

The flow tells a striking story about how India's chemical and pharmaceutical sector has embedded itself into global value chains. Swiss importers — pharmaceutical manufacturers, contract research organisations, and chemical processors — receive Indian-made intermediate compounds, then re-export finished or further-processed products worth $43.1 million to markets across Europe, North America, and Asia. This represents India's role not as a final-product exporter to Switzerland, but as a foundational supplier of specialty chemicals that Swiss companies transform and distribute worldwide.

The primary imports centre on amino-phenol derivatives and aromatic monoamines — complex organic compounds essential to drug synthesis. These are not finished medicines but the chemical building blocks that pharmaceutical manufacturers use to create active pharmaceutical ingredients, which then become drugs. India's advantage in this segment reflects decades of investment in fine chemicals manufacturing, cost-competitive production, and regulatory expertise.

A supply chain anchored in India's three pharmaceutical heartlands

India's pharmaceutical sector employed 1.14 million workers across the country in 2024, with the largest concentrations in Ahmedabad (Gujarat), Hyderabad (Telangana), and Mumbai (Maharashtra) — the three clusters driving this Switzerland-bound trade.

Ahmedabad has emerged as India's chemical synthesis capital, home to hundreds of small and mid-sized enterprises (SMEs) specialising in pharmaceutical intermediates and fine chemicals. Hyderabad, anchored by major pharmaceutical firms and contract manufacturers, focuses on active pharmaceutical ingredients and advanced intermediates. Mumbai remains the traditional pharmaceutical hub, with integrated manufacturers producing everything from bulk chemicals to finished formulations.

The sector is notably fragmented: 80 percent of pharmaceutical manufacturing is handled by small and medium enterprises, many of which are family-owned or operate as contract manufacturers for larger firms. This structure allows flexibility and rapid innovation, but also means thousands of smaller factories feed into export-oriented supply chains.

"India's pharmaceutical sector has moved beyond generic drug manufacture into specialty chemicals and high-value intermediates. The Swiss market values our technical capability and regulatory compliance."

Women comprise 30 percent of the pharmaceutical workforce across these clusters, concentrated in quality assurance, laboratory work, and packaging roles. The sector has seen steady growth in female chemists, analysts, and supervisory positions over the past decade.

Jobs, livelihoods, and community impact across Indian states

The $232.5 million export value to Switzerland represents real employment and income for workers and entrepreneurs across India. Using standard employment multipliers for the pharmaceutical chemicals sector:

• Direct employment: An estimated 815 workers directly engaged in producing, processing, and exporting these intermediate compounds to Switzerland. This includes chemists, technicians, quality control staff, logistics coordinators, and plant operators.
• Indirect employment: Approximately 2,105 additional jobs supported across supply chains — raw material suppliers, packaging manufacturers, logistics providers, testing laboratories, and warehousing operations.
• Total estimated impact: Around 2,920 jobs across India, predominantly in Gujarat, Telangana, and Maharashtra.

These are not abstract figures. In Ahmedabad's Torrent, Chem, and Macleods clusters, families depend on paycheques from intermediate chemical production. In Hyderabad's Genome Valley, research and manufacturing roles fund education and housing for thousands. In Mumbai's pharmaceutical belt, quality assurance roles — many held by women with chemistry or microbiology degrees — anchor middle-class livelihoods.

The 80-percent MSME share means that much of this employment supports owner-operated businesses. When a Ahmedabad fine chemical firm secures a repeat order from a Swiss importer, the owner hires additional production staff, orders raw materials from regional suppliers, and expands warehouse capacity. This multiplier effect extends beyond the factory gate into local economies.

India's standing in global pharmaceutical chemistry

India ranks 7th globally in pharmaceutical manufacturing employment and production volume. Switzerland's reliance on Indian intermediates reflects a global trend: Indian chemical and pharmaceutical firms have built scale, regulatory approval (FDA, EMA, WHO-prequalification certifications), and cost advantages that make them preferred suppliers for advanced economies.

The competitive landscape includes China, Germany, and the United States as alternative suppliers of pharmaceutical intermediates. However, India's pharmaceutical sector has expanded its market share in Europe over the past decade by combining price competitiveness with quality certifications and supply chain reliability. Swiss importers value the predictability and compliance track record of Indian manufacturers.

The re-export value ($43.1 million) shows that Switzerland functions as a value-adding node in the chain — Swiss firms receive Indian chemistry, combine it with local expertise, proprietary processes, or integration with other supply chains, then redistribute globally. This arrangement benefits both economies: India captures revenue from chemical manufacture, while Switzerland adds margin through formulation, distribution, and market access.

Forward trajectory and market opportunity

India's pharmaceutical sector continues to expand production capacity and move up the value chain toward more complex molecules. Pharmexcil's recent engagement with European buyers emphasizes specialty intermediates, contract manufacturing services, and regulatory support for Swiss and EU manufacturers seeking to diversify supply sources away from single-country dependence.

The Switzerland corridor illustrates a broader shift in how India participates in global drug supply chains. Rather than competing primarily on finished generic medicines, Indian firms are positioning themselves as reliable upstream suppliers to wealthy markets that need consistent, compliant sources of complex chemicals. For India's three pharmaceutical clusters, this means sustained manufacturing employment, investment in technical capability, and integration into high-value global networks.

The $232.5 million flow to Switzerland, modest by comparison to India's total pharmaceutical exports of $17 billion annually, nonetheless represents a solid and growing segment — precision chemicals for a precision market.